|
GB9803351D0
(en)
|
1998-02-17 |
1998-04-15 |
Oxford Biomedica Ltd |
Anti-viral vectors
|
|
EP1535995A1
(en)
*
|
1998-12-31 |
2005-06-01 |
Chiron Corporation |
Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof
|
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
|
AU2487300A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
AU2221600A
(en)
*
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
|
GB9906177D0
(en)
|
1999-03-17 |
1999-05-12 |
Oxford Biomedica Ltd |
Anti-viral vectors
|
|
AP1674A
(en)
|
1999-11-16 |
2006-10-30 |
Geneart Ag |
The genome of the HIV-1 inter-subtype (C/B') and use thereof.
|
|
US8202846B2
(en)
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
|
EP1272630A2
(en)
*
|
2000-03-16 |
2003-01-08 |
Genetica, Inc. |
Methods and compositions for rna interference
|
|
GB0009760D0
(en)
|
2000-04-19 |
2000-06-07 |
Oxford Biomedica Ltd |
Method
|
|
CA2731495C
(en)
*
|
2000-09-01 |
2015-02-03 |
Gen-Probe Incorporated |
Amplification of hiv-1 sequences for detection of sequences associated with drug-resistance mutations
|
|
JP2004508064A
(ja)
*
|
2000-09-15 |
2004-03-18 |
メルク エンド カムパニー インコーポレーテッド |
コドン最適化ｈｉｖ１−ｇａｇ、ｐｏｌ、ｎｅｆおよび修飾体を発現する増強された第１世代アデノウイルスワクチン
|
|
CA2422544A1
(en)
*
|
2000-09-22 |
2002-03-28 |
Virxsys |
Conditionally replicating viral vectors and their use
|
|
GB0024550D0
(https=)
|
2000-10-06 |
2000-11-22 |
Oxford Biomedica Ltd |
|
|
KR20030090626A
(ko)
|
2001-01-25 |
2003-11-28 |
비륵시스 코포레이션 |
유전자 기능을 동정하기 위한 방법 및 조성물
|
|
CA2344208A1
(en)
|
2001-04-30 |
2002-10-30 |
Oxford Biomedica (Uk) Limited |
Method
|
|
EP1411770A4
(en)
|
2001-07-05 |
2006-05-10 |
Chiron Corp |
POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
|
|
US6835568B2
(en)
|
2001-10-30 |
2004-12-28 |
Virxsys Corporation |
Regulated nucleic acid expression system
|
|
SI1504108T1
(sl)
|
2002-02-01 |
2013-07-31 |
Oxford Biomedica (Uk) Limited |
Lentiviralni vektor
|
|
GB0526211D0
(en)
*
|
2005-12-22 |
2006-02-01 |
Oxford Biomedica Ltd |
Viral vectors
|
|
WO2008134879A1
(en)
|
2007-05-04 |
2008-11-13 |
University Health Network |
Il-12 immunotherapy for cancer
|
|
US20090088625A1
(en)
*
|
2007-10-01 |
2009-04-02 |
Kenneth Oosting |
Photonic Based Non-Invasive Surgery System That Includes Automated Cell Control and Eradication Via Pre-Calculated Feed-Forward Control Plus Image Feedback Control For Targeted Energy Delivery
|
|
DK2307551T3
(en)
|
2008-06-18 |
2017-03-20 |
Oxford Biomedica (Uk) Ltd |
CLEANING RETROVIRAL VECTORS
|
|
US20120310140A1
(en)
|
2010-12-01 |
2012-12-06 |
Spinal Modulation, Inc. |
Directed delivery of agents to neural anatomy
|
|
GB201118636D0
(en)
|
2011-10-28 |
2011-12-07 |
Oxford Biomedica Ltd |
Nucleotide sequence
|
|
WO2014093965A1
(en)
*
|
2012-12-14 |
2014-06-19 |
Case Western Reserve University |
Genomic rna packaging enhancer element
|
|
AU2014255665B2
(en)
|
2013-04-18 |
2018-08-02 |
Fondazione Telethon |
Effective delivery of large genes by dual AAV vectors
|
|
GB201318804D0
(en)
|
2013-10-24 |
2013-12-11 |
Adaptimmune Ltd |
Vectors for transgene expression
|
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
|
LT3194434T
(lt)
|
2014-09-15 |
2019-09-25 |
Molmed Spa |
Chimeriniai antigeno receptoriai
|
|
GB201418965D0
(https=)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
CN113215115B
(zh)
|
2014-12-16 |
2024-07-02 |
C3J治疗公司 |
用于体外病毒基因组工程的组合物和方法
|
|
GB201519086D0
(en)
|
2015-10-28 |
2015-12-09 |
Syncona Partners Llp |
Gene Therapy
|
|
FI3380620T3
(fi)
|
2015-11-23 |
2024-08-01 |
Novartis Ag |
Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja
|
|
GB201604146D0
(en)
|
2016-03-10 |
2016-04-27 |
Nightstarx Ltd |
Prenylation assay
|
|
EP3318285A1
(en)
|
2016-11-08 |
2018-05-09 |
Oxford University Innovation Limited |
Treatment of eye disease
|
|
JP2020510611A
(ja)
|
2016-12-01 |
2020-04-09 |
ソシエテ・デ・プロデュイ・ネスレ・エス・アー |
Ｆａｍ４６ａを調節する方法
|
|
EP3375876A1
(en)
|
2017-03-13 |
2018-09-19 |
Evonetix Ltd |
Method for producing double stranded polynucleotides based on oligonucleotides with selected and different melting temperatures
|
|
WO2018178247A1
(en)
|
2017-03-31 |
2018-10-04 |
Nestec S.A. |
Methods of modulating ank1
|
|
IL270028B2
(en)
|
2017-04-21 |
2025-10-01 |
Ospedale San Raffaele Srl |
Garden care
|
|
JP7328211B2
(ja)
|
2017-04-24 |
2023-08-16 |
オスペダーレ サン ラファエレ エス．アール．エル |
Ｔｃｒ及びペプチド
|
|
WO2019068854A1
(en)
|
2017-10-06 |
2019-04-11 |
Ospedale San Raffaele S.R.L. |
GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
|
|
EP3697923A1
(en)
|
2017-10-17 |
2020-08-26 |
Nightstarx Limited |
Prenylation assay
|
|
WO2019101490A1
(en)
|
2017-11-21 |
2019-05-31 |
Nestec S.A. |
Methods of modulating alk
|
|
EP3696272A1
(en)
|
2017-12-22 |
2020-08-19 |
Oxford BioMedica (UK) Limited |
Retroviral vector
|
|
WO2019134866A1
(en)
|
2018-01-03 |
2019-07-11 |
Molmed Spa |
Chimeric antigen receptors containing optimal spacer region
|
|
JP7436383B2
(ja)
|
2018-04-18 |
2024-02-21 |
ユーシーエル ビジネス リミテッド |
操作された調節性ｔ細胞
|
|
SG11202011015QA
(en)
|
2018-05-15 |
2020-12-30 |
Flagship Pioneering Innovations V Inc |
Fusosome compositions and uses thereof
|
|
EP3794121A1
(en)
|
2018-05-17 |
2021-03-24 |
Société des Produits Nestlé S.A. |
Methods of modulating nkx6.3
|
|
KR20210016567A
(ko)
|
2018-05-30 |
2021-02-16 |
글리코스템 떼라퓨틱스 비.브이. |
Car nk 세포
|
|
CN112955174A
(zh)
|
2018-07-09 |
2021-06-11 |
旗舰先锋创新V股份有限公司 |
融合剂脂质体组合物和其用途
|
|
GB201814203D0
(en)
|
2018-08-31 |
2018-10-17 |
King S College London |
Engineered regulatory t cell
|
|
GB201817821D0
(en)
|
2018-10-31 |
2018-12-19 |
Ospedale San Raffaele Srl |
TCR and peptides
|
|
AU2019378883A1
(en)
|
2018-11-14 |
2021-06-03 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for T cell delivery
|
|
US20220008557A1
(en)
|
2018-11-14 |
2022-01-13 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for cns delivery
|
|
EP3880832A1
(en)
|
2018-11-14 |
2021-09-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for hematopoietic stem cell delivery
|
|
GB201900687D0
(en)
|
2019-01-17 |
2019-03-06 |
King S College London |
Immunotherapeutic methods and compositions
|
|
AU2019400930A1
(en)
|
2018-12-19 |
2021-07-01 |
King's College London |
Immunotherapeutic methods and compositions
|
|
GB201902277D0
(en)
|
2019-02-19 |
2019-04-03 |
King S College London |
Therapeutic agents
|
|
US20220175962A1
(en)
|
2019-03-10 |
2022-06-09 |
Sio Gene Therapies Inc. |
Gene therapy compositions and methods for treating parkinson's disease
|
|
GB201905301D0
(en)
|
2019-04-15 |
2019-05-29 |
Ospedale San Raffaele Srl |
Gene therapy
|
|
GB201907493D0
(en)
|
2019-05-28 |
2019-07-10 |
Ospedale San Raffaele |
Agents and methods for treating viral infections
|
|
GB201912515D0
(en)
|
2019-08-30 |
2019-10-16 |
King S College London |
Engineered regulatory T cell
|
|
CA3152525A1
(en)
|
2019-09-03 |
2021-03-11 |
Sana Biotechnology, Inc. |
Cd24-associated particles and related methods and uses thereof
|
|
WO2021094752A1
(en)
|
2019-11-12 |
2021-05-20 |
Oxford Biomedica (Uk) Limited |
Production system
|
|
EP4103723A1
(en)
|
2020-02-13 |
2022-12-21 |
Oxford BioMedica (UK) Limited |
Production of lentiviral vectors
|
|
CN115427440A
(zh)
|
2020-02-25 |
2022-12-02 |
圭尔医疗有限公司 |
用于工程化细胞的嵌合受体
|
|
DE102020111571A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
|
DE102020106710A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
|
WO2021181108A1
(en)
|
2020-03-13 |
2021-09-16 |
Oxford Biomedica (Uk) Limited |
Lentiviral vectors
|
|
CA3178308A1
(en)
|
2020-03-31 |
2021-10-07 |
Sana Biotechnology, Inc. |
Targeted lipid particles and compositions and uses thereof
|
|
AU2021264465A1
(en)
|
2020-04-27 |
2022-12-15 |
University Of Iowa Research Foundation |
Compositions and methods for the treatment of cystic fibrosis
|
|
GB202007169D0
(en)
|
2020-05-14 |
2020-07-01 |
Ospedale San Raffaele Srl |
Epidermal growth factor receptor
|
|
GB202007199D0
(en)
|
2020-05-15 |
2020-07-01 |
Oxford Biomedica Ltd |
Viral vector production
|
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
|
GB202013477D0
(en)
|
2020-08-27 |
2020-10-14 |
Quell Therapeutics Ltd |
Nucleic acid constructs for expressing polypeptides in cells
|
|
WO2022047316A1
(en)
|
2020-08-28 |
2022-03-03 |
Sana Biotechnology, Inc. |
Modified anti-viral binding agents
|
|
GB202017725D0
(en)
|
2020-11-10 |
2020-12-23 |
Oxford Biomedica Ltd |
Method
|
|
GB202018657D0
(en)
|
2020-11-26 |
2021-01-13 |
Ospedale San Raffaele Srl |
Agents and methods for increasing liver immune response
|
|
EP4267601A1
(en)
|
2020-12-23 |
2023-11-01 |
Quell Therapeutics Limited |
Inducible signalling protein
|
|
MX2023008081A
(es)
|
2021-01-11 |
2023-09-12 |
Sana Biotechnology Inc |
Uso de vectores virales dirigidos a cd8.
|
|
CA3207166A1
(en)
|
2021-02-01 |
2022-08-04 |
Angelo Leone Lombardo |
Gene silencing
|
|
CA3207426A1
(en)
|
2021-02-15 |
2022-08-18 |
Vania Broccoli |
Epigenetic silencing for treatment of cancer
|
|
GB202102637D0
(en)
|
2021-02-24 |
2021-04-07 |
Quell Therapeutics Ltd |
Engineered regulatory t cell
|
|
IL308356A
(en)
|
2021-05-12 |
2024-01-01 |
Fond Telethon |
Vector system
|
|
JP2024521811A
(ja)
|
2021-05-28 |
2024-06-04 |
サナ バイオテクノロジー，インコーポレイテッド |
短縮型ヒヒ内在性レトロウイルス（ＢａＥＶ）エンベロープ糖タンパク質を含む脂質粒子、ならびに関連する方法及び使用
|
|
EP4381081A1
(en)
|
2021-08-04 |
2024-06-12 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
TW202321286A
(zh)
|
2021-09-21 |
2023-06-01 |
英商圭爾醫療有限公司 |
抗p75ntr嵌合抗原受體
|
|
EP4405385A1
(en)
|
2021-09-21 |
2024-07-31 |
Quell Therapeutics Limited |
Anti-trem2 chimeric antigen receptor
|
|
GB202114532D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral Vectors
|
|
GB202114529D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB202114528D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB202114530D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Retroviral vectors
|
|
GB202114534D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Novel viral regulatory elements
|
|
US20250000966A1
(en)
*
|
2021-10-13 |
2025-01-02 |
The Cleveland Clinic Foundation |
Mrna vaccine design via the alteration of codon usage
|
|
US20250230511A1
(en)
|
2021-10-29 |
2025-07-17 |
Sana Biotechnology, Inc. |
Methods and reagents for amplifying viral vector nucleic acid products
|
|
GB202117298D0
(en)
|
2021-11-30 |
2022-01-12 |
Quell Therapeutics Ltd |
Signalling protein
|
|
WO2023114949A1
(en)
|
2021-12-16 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and systems of particle production
|
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
US20250059239A1
(en)
|
2021-12-17 |
2025-02-20 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
EP4453022A1
(en)
|
2021-12-22 |
2024-10-30 |
Quell Therapeutics Limited |
Constitutive cytokine receptors
|
|
EP4209511A1
(en)
|
2022-01-05 |
2023-07-12 |
Gyala Therapeutics Sociedad Limitada |
Anti-cd84 antibodies amd chimeric antigen receptors
|
|
AU2023205629A1
(en)
|
2022-01-05 |
2024-08-15 |
Fundació De Recerca Clinic Barcelona-Institut D’Investigacions Biomèdiques August Pi I Sunyer |
Anti-cd84 antibodies and chimeric antigen receptors
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4472646A1
(en)
|
2022-02-01 |
2024-12-11 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
EP4269426A1
(en)
|
2022-04-29 |
2023-11-01 |
Ospedale San Raffaele S.r.l. |
Gene therapy
|
|
EP4551253A1
(en)
|
2022-07-08 |
2025-05-14 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes
|
|
EP4303226A1
(en)
|
2022-07-08 |
2024-01-10 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes and epigenetic silencers for the treatment of disorders
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
WO2024033544A1
(en)
|
2022-08-12 |
2024-02-15 |
Ospedale San Raffaele S.R.L. |
Deglycosylation of native glycoproteins expressed on a tumor cell surface
|
|
GB202211935D0
(en)
|
2022-08-16 |
2022-09-28 |
Oxford Biomedica Ltd |
envelope proteins
|
|
US20260055146A1
(en)
|
2022-08-24 |
2026-02-26 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
WO2024100145A1
(en)
|
2022-11-08 |
2024-05-16 |
Ospedale San Raffaele S.R.L. |
Polynucleotide and vector
|
|
AU2023377353A1
(en)
|
2022-11-11 |
2025-05-22 |
Ospedale San Raffaele S.R.L. |
Cdh17 car
|
|
GB202217541D0
(en)
|
2022-11-24 |
2023-01-11 |
Quell Therapeutics Ltd |
Recombinant receptor
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
WO2024133472A1
(en)
|
2022-12-22 |
2024-06-27 |
Quell Therapeutics Limited |
Constitutive cytokine receptors
|
|
EP4651887A1
(en)
|
2023-01-16 |
2025-11-26 |
Ospedale San Raffaele S.r.l. |
T-cell receptors
|
|
EP4403580A1
(en)
|
2023-01-23 |
2024-07-24 |
Medizinische Hochschule Hannover |
Anti-entpd3 chimeric antigen receptor
|
|
CN120981484A
(zh)
|
2023-01-23 |
2025-11-18 |
汉诺威医学院 |
抗entpd3嵌合抗原受体
|
|
AU2024219048A1
(en)
|
2023-02-07 |
2025-08-07 |
Quell Therapeutics Limited |
Culture method for treg cells
|
|
WO2024175805A1
(en)
|
2023-02-24 |
2024-08-29 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
EP4420676A1
(en)
|
2023-02-24 |
2024-08-28 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
EP4680728A1
(en)
|
2023-03-17 |
2026-01-21 |
Quell Therapeutics Limited |
Treg therapy
|
|
WO2024194223A2
(en)
|
2023-03-17 |
2024-09-26 |
Ospedale San Raffaele S.R.L. |
Gene therapy
|
|
WO2024194355A1
(en)
|
2023-03-20 |
2024-09-26 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
EP4434539A1
(en)
|
2023-03-20 |
2024-09-25 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
CN121219020A
(zh)
|
2023-03-22 |
2025-12-26 |
圣拉斐尔医院有限责任公司 |
基因疗法
|
|
WO2024194642A1
(en)
|
2023-03-22 |
2024-09-26 |
Quell Therapeutics Limited |
Engineered t regulatory cell
|
|
WO2024194649A1
(en)
|
2023-03-22 |
2024-09-26 |
Quell Therapeutics Limited |
Engineered t cells and uses thereof
|
|
EP4698666A1
(en)
|
2023-04-18 |
2026-02-25 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220597A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Digital droplet based assay for detecting replication competent lentiviral vector
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
GB202307366D0
(en)
|
2023-05-17 |
2023-06-28 |
Ospedale San Raffaele Srl |
Vector
|
|
EP4716750A1
(en)
|
2023-05-23 |
2026-04-01 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
WO2024259299A1
(en)
|
2023-06-14 |
2024-12-19 |
The Broad Institute, Inc. |
Compositions and methods for identification of vhh antibodies that bind a target antigen
|
|
CN121586727A
(zh)
|
2023-06-21 |
2026-02-27 |
圭尔医疗有限公司 |
组成型细胞因子受体
|
|
AU2024305679A1
(en)
|
2023-06-28 |
2026-01-22 |
Ospedale San Raffaele S.R.L. |
T-cell receptors
|
|
WO2025032194A1
(en)
|
2023-08-08 |
2025-02-13 |
Ospedale San Raffaele S.R.L. |
T-cell receptors
|
|
GB202316264D0
(en)
|
2023-10-24 |
2023-12-06 |
Ospendale San Raffaele S R L |
Gene therapy
|
|
IT202300022191A1
(it)
|
2023-10-24 |
2025-04-24 |
Fond Telethon Ets |
Mezzi e metodi per la modifica genetica di uba1
|
|
WO2025109189A1
(en)
|
2023-11-24 |
2025-05-30 |
Ospedale San Raffaele S.R.L. |
Engineered regulatory t cells and uses thereof
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
EP4640830A1
(en)
|
2024-04-23 |
2025-10-29 |
Fondazione Telethon ETS |
Means and methods for safe and efficient gene editing in cells
|
|
WO2026008994A1
(en)
|
2024-07-04 |
2026-01-08 |
Quell Therapeutics Limited |
Expression construct
|
|
WO2026027876A1
(en)
|
2024-07-29 |
2026-02-05 |
Quell Therapeutics Limited |
Chimeric antigen receptor
|
|
GB202411558D0
(en)
|
2024-08-06 |
2024-09-18 |
Quell Therapeutics Ltd |
Culture method
|
|
GB202415025D0
(en)
|
2024-10-11 |
2024-11-27 |
Ospedale San Raffaele Srl |
Cell
|